Mast Cell Stabilizers for Cardiovascular Disease Prevention
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for cardiovascular diseases, particularly atherosclerosis and abdominal aortic aneurysms, do not effectively target mast cells, which are implicated in the development and progression of these conditions.
Innovation Solution
Administering mast cell stabilizers such as cromolyn, nedocromil, ketotifen, or lodoxamide to reduce the risk of aneurysm formation and atherosclerotic plaque development by stabilizing mast cells, thereby preventing the progression of cardiovascular diseases.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional treatments (cholesterol-lowering medications, blood pressure medications, surgical techniques) are used for cardiovascular disease, then traditional cardiovascular risk factors are addressed, but mast cell-mediated inflammation and vascular wall remodeling are not targeted
Solution Approach 1:
The patent introduces mast cell stabilizers as intermediary agents that bridge the gap between conventional cardiovascular treatments and mast cell-mediated pathological processes. These stabilizers act as mediators that prevent mast cell degranulation and the release of inflammatory mediators, thereby connecting traditional risk factor management with novel anti-inflammatory therapy targeting the mast cell pathway.
2Reliability
If mast cell stabilizers are administered to prevent aneurysm formation and atherosclerotic plaque development, then new therapeutic efficacy is achieved, but deviation from established treatment protocols occurs
Solution Approach 1:
The patent applies preliminary action by administering mast cell stabilizers before the full development of atherosclerotic plaques or aneurysms. The stabilizers are given prophylactically to prevent mast cell activation and the subsequent inflammatory cascade that leads to vascular wall remodeling, plaque formation, and aneurysm development, rather than treating established disease.
3Adaptability or versatility
If mast cell stabilizing drugs marketed for allergies are repurposed for cardiovascular disease, then treatment versatility is improved, but lack of cardiovascular-specific optimization remains
Solution Approach 1:
The patent exploits the universality of mast cell stabilizers by demonstrating their multi-functional applicability. The same drugs that stabilize mast cells in allergic conditions also prevent mast cell-mediated inflammation in cardiovascular disease, revealing a universal mechanism of action that transcends traditional indication boundaries and allows one drug to serve multiple therapeutic purposes.
Data Source
AI summary
The present invention is directed to methods of treating or preventing the development of cardiovascular disease by administering compounds that stabilize mast cells. In addition, it includes pharmaceutical compositions which have both a mast cell stabilizer and instructions regarding the use of the stabilizer in treating or preventing cardiovascular disease. The methods and compositions will be of particular value for preventing aneurysms of the abdominal aorta in individuals with atherosclerosis, diabetes, hypertension or a family history of aneurysms.